Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Takeda
- 12 May 2022 Planned number of patients changed from 302 to 402.
- 12 May 2022 Planned End Date changed from 9 Oct 2023 to 18 Jul 2028.
- 12 May 2022 Planned primary completion date changed from 14 Aug 2023 to 23 May 2028.